Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib ± Cetrelimab ± Platinum Chemotherapy in Metastatic or Locally Advanced Urothelial Cancer
2023-510295-31-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of erdafitinib in transitional cell carcinoma (TCC) and urothelial carcinoma (UC) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting toxicities in Phase 1b, Overall response rate in Phase 2 (RECIST 1.1, investigator-assessed) and 1 more. Planned start Mar 2024; status: authorised.
02
Drugs
erdafitinib
03
Conditions
transitional cell carcinoma (TCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on 2023-510295-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510295-31-00.